Literature DB >> 14642593

QSAR study on some pyridoacridine ascididemin analogues as anti-tumor agents.

Bikash Debnath1, Shovanlal Gayen, Subrata Bhattacharya, Soma Samanta, Tarun Jha.   

Abstract

Pyridoacridine ascididemin analogues have been reported as anticancer agents for their interesting antitumor activity against human cancer cells. A quantitative structure-activity relationship (QSAR) analysis of ascididemin analogues was attempted using the physicochemical parameters and the electrotopological state atom (ETSA) indices. This study indicates that the electron withdrawing substituents with higher MR (molar refractivity) value at R(1) position favor the anti-tumor activity and the presence of NHR (R is hydrogen or alkyl group) at the R(3) position has contribution to the anti-tumor activity. ETSA indices have been incorporated as independent variable in the QSAR model with physicochemical parameters. It clearly suggests the importance of atoms 2, 3, 4, 5, 6 and 7 to the anti-tumor activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642593     DOI: 10.1016/j.bmc.2003.09.022

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Quantitative structure-activity relationship study on some benzodiazepine derivatives as anti-Alzheimer agents.

Authors:  Bikash Debnath; Shovanlal Gayen; Anindya Basu; Kolluru Srikanth; Tarun Jha
Journal:  J Mol Model       Date:  2004-09-17       Impact factor: 1.810

2.  Databases and QSAR for cancer research.

Authors:  Adeel Malik; Hemajit Singh; Munazah Andrabi; Syed Akhtar Husain; Shandar Ahmad
Journal:  Cancer Inform       Date:  2007-02-15

Review 3.  A mini review on pyridoacridines: Prospective lead compounds in medicinal chemistry.

Authors:  Vikas Sharma; Prabodh C Sharma; Vipin Kumar
Journal:  J Adv Res       Date:  2014-11-15       Impact factor: 10.479

Review 4.  New Perspectives in the Chemistry of Marine Pyridoacridine Alkaloids.

Authors:  Alois Plodek; Franz Bracher
Journal:  Mar Drugs       Date:  2016-01-26       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.